NATIONAL CELEBRATION OF HOPE Together, we can break through limits. There is only one way to solve the impossible. Together. Imagine a world where every lung cancer patient is screened one goal: to double long-term survival in lung cancer by 2025. before the disease spreads. Where every patient gets the right Through initiatives that increase early diagnosis, accelerate drug at the right time, and the goal of any treatment plan is to delivery of innovative precision medicines and improve quality cure. Where every patient, everywhere in the world, can expect care, we believe there is a way to solve the seemingly impossible to receive the highest quality care that provides the best odds and ultimately eliminate lung cancer as a cause of death. in the fight against the disease.Where no patient dies from lung cancer. Please visit LungAmbitionAlliance.org to know more about our first projects and help shape our priorities. Your insights will serve Together, AstraZeneca, the International Association for the Study as an important first step on our life-changing journey toward of Lung Cancer, the Global Lung Cancer Coalition and Guardant accomplishing the impossible … together. Health have come to form the Lung Ambition Alliance. We share Join us at LungAmbitionAlliance.org. US-46153 Last Updated 10/20 NATIONAL CELEBRATION OF HOPE LUNGevity Foundation October 21, 2020 CHAIRS Brent Barnhart Vice President, UBS, Private Management Nancy Cohen Lung Cancer Patient and Advocate Andre Owens Partner, WilmerHale Natalie Cohen Smith Senior Vice President, Consero President and CEO LUNGevity Foundation Andrea E. Ferris Dear Friends, On behalf of LUNGevity, thank you for being a part of our National LUNGevity offers programs and services for anyone affected by lung Celebration of Hope. While the COVID-19 crisis is keeping us from cancer. We provide extensive educational resources, online peer-to- being together today in person, it cannot stop us from celebrating peer support, and in-person survivorship programs, while building a progress for lung cancer patients and honoring those who have a community of empowerment and hope. meaningful impact on the lung cancer community. Each year, we pay tribute to the tireless and unwavering dedication This year there is much to celebrate and be hopeful about — so many of individuals and businesses. This year, we are delighted to honor advances in all areas of diagnosis and treatment. So far in 2020, we super-advocate Jill Feldman, lung cancer patient and co-founder of have seen 11 new lung cancer treatment approaches approved by the patient group EGFR Resisters, outstanding volunteer Kathy Cuddy, US FDA — and many more are in development. Guidelines for the and the incredibly dedicated oncologist, Dr. Fred Smith. Today we early detection of lung cancer are potentially being expanded so even honor AstraZeneca for its corporate leadership in exemplifying more people can be screened early, and we have seen a heightened extraordinary commitment to improving outcomes for lung focus on inclusion and diversity to ensure that ALL people diagnosed cancer patients. with lung cancer have access to optimal care. I am so grateful to our event co-chairs, Brent Barnhardt, VP, UBS Research is the key to these advances, resulting in improved Private Management; Nancy Cohen, lung cancer patient and survivorship and quality of life for people diagnosed with the disease. advocate; Andre Owens, Partner, WIlmerHale, and LUNGevity Board Member; and Natalie Cohen Smith, Sr. VP, Consero. My thanks also go In 2020, we held our first virtual International Lung Cancer to our National Celebration of Hope sponsors and supporters. Your Survivorship Conference, providing expert information, support, and generosity is appreciated by all of us working for a better future for community for over 1,300 patients and caregivers from 38 countries. those affected by lung cancer. Many of these participants were stage IV patients who would have been unable to travel to our in-person event, so we have decided LUNGevity is moving forward toward a world where no one dies of to continue holding a virtual event in addition to an in-person lung cancer. With each passing year, your support is making this goal conference going forward to better serve our patient population. more attainable. Since its founding, LUNGevity Foundation has helped change the trajectory of the lung cancer community. Our impact can be seen in Sincerely, many ways: the successes of our research awardees, our collaboration with Stand Up To Cancer on the first Lung Cancer Interception Dream Team, the thousands of supporters who walk to raise awareness at Andrea E. Ferris our grassroots Breathe Deep events, this year virtually, and the many President and CEO who have made more proactive, educated treatment decisions as a LUNGevity Foundation result of our educational and support resources. Chairman, Scientific Advisory Board LUNGevity Foundation Charles M. Rudin, MD, PhD Dear Friends of LUNGevity, Thank you for joining us to celebrate the progress in lung cancer from Stanford University School of Medicine and a member of the research over the past year. Stand Up To Cancer-ALA-LUNGevity Dream Team. Their expertise will help guide the Foundation’s scientific strategy and selection of grants These are challenging times for all of us. Yet, despite the COVID-19 for LUNGevity’s Translational Research Program, which is driving pandemic, there is much to be hopeful about — especially for the research results out of laboratories and into the clinics. lung cancer community. I’m proud to say that LUNGevity continues to fund vital lung cancer research with the ability to improve patient This year saw exciting progress in many areas of scientific research. outcomes. Our programmatic focus remains on finding lung cancer KRAS, a mutation found in 25% of lung cancers, was considered not early and treating it more effectively. druggable, but drugs targeting specific KRAS mutations have shown promise in early clinical trials and are now moving to larger trials. New LUNGevity is funding research that will help people live better with drug approvals were given to treat two rare mutations — MET and lung cancer. We recently granted three Career Development Awards, RET. We now have more immunotherapy options for patients with our 9th class of exceptional young researchers. These young advanced-stage lung cancer. investigators are working in key areas of lung cancer research: one working to understand and prevent resistance to drugs targeting the Even in difficult times, we have much reason for hope. Organizations KRAS mutation, and two seeking to develop novel strategies to like LUNGevity are driving change, funding outstanding researchers, enhance the benefits of immunotherapy — through combination with and empowering patients and caregivers with knowledge and DNA damage response inhibitors for small cell lung cancer or with support. Your generosity makes this change possible — and the future radiation for non-small cell lung cancer. Our funding of this year’s brighter. Thank you. group of incredibly accomplished young researchers will help make progress in solving these challenges and continue to improve Sincerely, outcomes for lung cancer patients. LUNGevity also welcomed two prestigious new members to the Foundation’s Scientific Advisory Board this year. Christine M. Lovly, Charles M. Rudin, MD, PhD MD, PhD, is a physician scientist and co-leader of the Translational Professor and Chief, Thoracic Oncology Service Research and Interventional Oncology Program at Vanderbilt-Ingram Memorial Sloan Kettering Cancer Center Cancer Center and a past recipient of LUNGevity’s Career Development Award. Maximilian Diehn, MD, is a radiation oncologist Gala Chairs Brent Barnhart Nancy Cohen Andre Owens Natalie Cohen Smith Hello Friends, This year surely looks different than most, but the feelings of It is with gratitude that we welcome you to this year’s hope, support, and community that are hallmarks of our National Celebration of Hope, and we thank you for choosing annual Celebration of Hope remain the same. It is an honor to support LUNGevity. Like us, many of you have a personal to be joining you virtually to celebrate the advancements connection to lung cancer — a family member, a friend, a made in lung cancer research, as well as honor those who are co-worker, or maybe even yourself. We want you to know making a difference in the lives of people living with lung that LUNGevity is there for you, raising awareness that this cancer. This year we have guests joining us from coast-to- No. 1 cancer killer in America can affect ANYONE who coast, and we are thrilled to be welcoming our virtual has lungs! viewers from wherever they call home. It is exciting to have so many new supporters and the opportunity to share the important work of our honorees and LUNGevity with an Warmly, expansive audience. We come to you as a group that has strong and unique ties to LUNGevity and the lung cancer community at large. As a Brent Barnhart lung cancer patient, a caregiver, the son of a patient, and a friend of a patient, our lives have been irrevocably changed by the disease. Yet, we have gathered here today because, Nancy Cohen thanks to the work of scientists, doctors, advocates, and policy leaders, the future for lung cancer patients is changing. Now more than ever, there is HOPE for better Andre Owens outcomes and a better way of life for those affected by the disease. Natalie Cohen Smith OUR VISION IS A WORLD WHERE NO ONE DIES OF LUNG CANCER. LUNGevity is focused on: Improving outcomes for people diagnosed with lung cancer and improving the way that people live with lung cancer. ___ LUNGevity impacts the lung cancer community through research, education, and support. ___ For every $1 LUNGevity invests in research, scientists are able to garner an additional $12 of funding to continue their research — this is a 12:1 return on investment.